Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

MARUCCO D AGUILAR; L VERONESE; DE REQUENA DG; Stefano BONORA; Andrea CALCAGNO; I CAVECCHIA; Alessandro SINICCO; Francesco Giuseppe DE ROSA; G CARITI; Giovanni DI PERRI

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

MARUCCO D AGUILAR
, L VERONESE
, DE REQUENA DG
, Stefano BONORA
, Andrea CALCAGNO
, I CAVECCHIA
, Alessandro SINICCO
, Francesco Giuseppe DE ROSA
, G CARITI
, Giovanni DI PERRI

Department of Translational Medicine

Research output: Contribution to journal › Article

Abstract

OBJECTIVES: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. PATIENTS AND METHODS: In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy. RESULTS: We observed a significant HIV-RNA decrease (>1 log(10) copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose. CONCLUSIONS: A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.

Original language	English
Pages (from-to)	565-568
Number of pages	4
Journal	Journal of Antimicrobial Chemotherapy
Volume	59
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://hdl.handle.net/11579/216807

Cite this

@article{42079e99c60947bcbb7f5fdd6afa68c1,

title = "Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus",

abstract = "OBJECTIVES: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. PATIENTS AND METHODS: In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy. RESULTS: We observed a significant HIV-RNA decrease (>1 log(10) copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose. CONCLUSIONS: A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.",

author = "AGUILAR, \{MARUCCO D\} and L VERONESE and DG, \{DE REQUENA\} and Stefano BONORA and Andrea CALCAGNO and I CAVECCHIA and Alessandro SINICCO and \{DE ROSA\}, \{Francesco Giuseppe\} and G CARITI and \{DI PERRI\}, Giovanni",

year = "2007",

language = "English",

volume = "59",

pages = "565--568",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

AU - AGUILAR, MARUCCO D

AU - VERONESE, L

AU - DG, DE REQUENA

AU - BONORA, Stefano

AU - CALCAGNO, Andrea

AU - CAVECCHIA, I

AU - SINICCO, Alessandro

AU - DE ROSA, Francesco Giuseppe

AU - CARITI, G

AU - DI PERRI, Giovanni

PY - 2007

Y1 - 2007

N2 - OBJECTIVES: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. PATIENTS AND METHODS: In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy. RESULTS: We observed a significant HIV-RNA decrease (>1 log(10) copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose. CONCLUSIONS: A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.

AB - OBJECTIVES: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. PATIENTS AND METHODS: In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy. RESULTS: We observed a significant HIV-RNA decrease (>1 log(10) copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose. CONCLUSIONS: A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.

UR - https://iris.uniupo.it/handle/11579/216807

M3 - Article

SN - 0305-7453

VL - 59

SP - 565

EP - 568

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

ER -

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this